celecoxib has been researched along with Colitis in 16 studies
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study tried to investigate whether an apple oligogalactan (AOG) could enhance the growth inhibitory effect of celecoxib on colorectal cancer." | 7.80 | An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer. ( Chen, J; Li, Q; Li, Y; Liu, L; Mei, L; Mei, Q; Niu, Y; Sun, Y; Zhang, B; Zhang, R, 2014) |
| " The aim of this study was 1) to evaluate the relative importance of the GI microflora on the experimental colonic damage in the presence of caused by NSAID, and 2) to assess the efficacy of antibiotic treatment with ampicillin on the process of healing of colitis." | 7.77 | Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. ( Brzozowski, T; Drozdowicz, D; Karczewska, E; Konturek, SJ; Krzysiek-Maczka, G; Pajdo, R; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z; Urbanczyk, K; Zwolinska-Wcislo, M, 2011) |
| "To assess the mechanism of exacerbation of colonic damage in rat colitis model induced by trinitrobenzene sulfonic acid (TNBS) treated with celecoxib (a selective COX-2 inhibitor)." | 7.74 | [Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib]. ( Dong, Xy; Lv, Ym; Ye, Sm; Zhang, L, 2008) |
| "To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS)." | 7.72 | Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. ( Dong, XY; Lu, YM; Zhang, L, 2004) |
| " Here, we investigate the effects of the selective cyclo-oxygenase-2 inhibitor, celecoxib, in rats subjected to experimental colitis." | 7.71 | Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. ( Caputi, AP; Centorrino, T; Ciccolo, A; Cuzzocrea, S; Dugo, L; Mazzon, E; Sautebin, L; Serraino, I, 2001) |
| "Acetic acid treatment caused haemorrhagic diarrhoea and weight loss in rats." | 5.33 | The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. ( Arafa, M; El-Medany, A; Mahgoub, A; Morsi, M; Mustafa, A, 2005) |
| " Colonic delivery of celecoxib elicits anticolitic effects in a trinitrobenzene sulfonic acid-induced rat colitis model." | 3.81 | Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target. ( Jeong, S; Jung, Y; Kim, MS; Kim, W; Lee, S; Lee, Y; Moon, HR; Nam, J; Yoo, JW, 2015) |
| " This study tried to investigate whether an apple oligogalactan (AOG) could enhance the growth inhibitory effect of celecoxib on colorectal cancer." | 3.80 | An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer. ( Chen, J; Li, Q; Li, Y; Liu, L; Mei, L; Mei, Q; Niu, Y; Sun, Y; Zhang, B; Zhang, R, 2014) |
| " The aim of this study was 1) to evaluate the relative importance of the GI microflora on the experimental colonic damage in the presence of caused by NSAID, and 2) to assess the efficacy of antibiotic treatment with ampicillin on the process of healing of colitis." | 3.77 | Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. ( Brzozowski, T; Drozdowicz, D; Karczewska, E; Konturek, SJ; Krzysiek-Maczka, G; Pajdo, R; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z; Urbanczyk, K; Zwolinska-Wcislo, M, 2011) |
| "To assess the mechanism of exacerbation of colonic damage in rat colitis model induced by trinitrobenzene sulfonic acid (TNBS) treated with celecoxib (a selective COX-2 inhibitor)." | 3.74 | [Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib]. ( Dong, Xy; Lv, Ym; Ye, Sm; Zhang, L, 2008) |
| " Celecoxib (10, 20 and 40 mg/kg(-l)) was significantly more potent at aggravating ischemia-reperfusion injury as compared to nimesulide." | 3.73 | Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. ( Malhotra, S; Nada, R; Pandhi, P; Shafiq, N, 2005) |
| "To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS)." | 3.72 | Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. ( Dong, XY; Lu, YM; Zhang, L, 2004) |
| " Here, we investigate the effects of the selective cyclo-oxygenase-2 inhibitor, celecoxib, in rats subjected to experimental colitis." | 3.71 | Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. ( Caputi, AP; Centorrino, T; Ciccolo, A; Cuzzocrea, S; Dugo, L; Mazzon, E; Sautebin, L; Serraino, I, 2001) |
| "Colitis was induced by intracolonic administration of trinitrobenzene sulfonic acid." | 1.31 | Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. ( Ajuebor, MN; Singh, A; Wallace, JL, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kaur, R | 1 |
| Desai, D | 1 |
| Amin, S | 1 |
| Raza, K | 1 |
| Bhalla, A | 1 |
| Yadav, P | 1 |
| Kaushal, N | 1 |
| Li, Y | 1 |
| Niu, Y | 1 |
| Sun, Y | 1 |
| Mei, L | 1 |
| Zhang, B | 1 |
| Li, Q | 1 |
| Liu, L | 1 |
| Zhang, R | 1 |
| Chen, J | 1 |
| Mei, Q | 1 |
| Lee, Y | 2 |
| Kim, W | 2 |
| Hong, S | 1 |
| Park, H | 1 |
| Yum, S | 1 |
| Yoon, JH | 1 |
| Jung, Y | 2 |
| Setia, S | 1 |
| Nehru, B | 1 |
| Sanyal, SN | 1 |
| Lee, S | 1 |
| Nam, J | 1 |
| Jeong, S | 1 |
| Yoo, JW | 1 |
| Kim, MS | 1 |
| Moon, HR | 1 |
| Pallio, G | 1 |
| Bitto, A | 1 |
| Pizzino, G | 1 |
| Galfo, F | 1 |
| Irrera, N | 1 |
| Minutoli, L | 1 |
| Arcoraci, V | 1 |
| Squadrito, G | 1 |
| Macrì, A | 1 |
| Squadrito, F | 1 |
| Altavilla, D | 1 |
| Carothers, AM | 1 |
| Davids, JS | 1 |
| Damas, BC | 1 |
| Bertagnolli, MM | 1 |
| Zwolinska-Wcislo, M | 1 |
| Krzysiek-Maczka, G | 1 |
| Ptak-Belowska, A | 1 |
| Karczewska, E | 1 |
| Pajdo, R | 1 |
| Sliwowski, Z | 1 |
| Urbanczyk, K | 1 |
| Drozdowicz, D | 1 |
| Konturek, SJ | 1 |
| Pawlik, WW | 1 |
| Brzozowski, T | 1 |
| Hegazi, RA | 1 |
| Mady, HH | 1 |
| Melhem, MF | 1 |
| Sepulveda, AR | 1 |
| Mohi, M | 1 |
| Kandil, HM | 1 |
| Zhang, L | 2 |
| Lu, YM | 1 |
| Dong, XY | 2 |
| El-Medany, A | 1 |
| Mahgoub, A | 1 |
| Mustafa, A | 1 |
| Arafa, M | 1 |
| Morsi, M | 1 |
| Shafiq, N | 1 |
| Malhotra, S | 1 |
| Pandhi, P | 1 |
| Nada, R | 1 |
| Houmani, Z | 1 |
| Imbert, A | 1 |
| Duchmann, JC | 1 |
| Messerschmitt, C | 1 |
| Barbare, JC | 1 |
| Latrive, JP | 1 |
| Biour, M | 1 |
| Lv, Ym | 1 |
| Ye, Sm | 1 |
| Ajuebor, MN | 1 |
| Singh, A | 1 |
| Wallace, JL | 1 |
| Cuzzocrea, S | 1 |
| Mazzon, E | 1 |
| Serraino, I | 1 |
| Dugo, L | 1 |
| Centorrino, T | 1 |
| Ciccolo, A | 1 |
| Sautebin, L | 1 |
| Caputi, AP | 1 |
16 other studies available for celecoxib and Colitis
| Article | Year |
|---|---|
Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis; Coli | 2023 |
An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Celecoxib; Cell Proliferation | 2014 |
Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cell Line; Colitis; Colon; Cyclooxygenase 2 Inhibi | 2014 |
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor.
Topics: Animals; Celecoxib; Chemoprevention; Colitis; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Mice; | 2014 |
Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cell Line; Colitis; Colon; Drug Delivery Systems; Drug | 2015 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin | 2016 |
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
Topics: Animals; Antigens, CD34; Celecoxib; Cell Transformation, Neoplastic; Colitis; Colonic Neoplasms; Cyc | 2010 |
Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacter | 2011 |
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Topics: Animals; Celecoxib; Colitis; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal | 2003 |
Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.
Topics: Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Inflam | 2004 |
The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats.
Topics: Acetic Acid; Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Lactones; Male; Pyrazoles; Rats | 2005 |
Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors.
Topics: Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Gastric Mucosa; Gastrointestinal Tract; Indo | 2005 |
[Acute colitis closely following the beginning of celecoxib treatment].
Topics: Acute Disease; Aged, 80 and over; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Bac | 2005 |
[Mechanism of exacerbation of colonic damage in experimental colitis treated with celecoxib].
Topics: Animals; Celecoxib; Colitis; Colon; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Male; Pyrazoles; Ra | 2008 |
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis.
Topics: Animals; Blotting, Western; Celecoxib; Colitis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2000 |
Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonates; Body Weight; Celecoxib; Colitis | 2001 |